Stocks Health care SERA
NASDAQ · Health careSera Prognostics, Inc. (SERA)
Sera Prognostics, Inc. brought in $70K of revenue over the twelve months to June 30, 2026, down 35.2% from a year earlier. It posted a net loss of $33.2M. In fiscal 2025 capital spending exceeded operating cash flow by $26.3M. At June 30, 2026 it held $4.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Sera Prognostics, Inc.
- Net worth
- Sera Prognostics, Inc. has a market value (market cap) of $86.4M at the latest share price, and shareholders' equity of $59.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $81K (+5.2% year on year), with a net loss of $31.9M. Over the 12 months to June 30, 2026: revenue $70K, net loss $33.2M.
- Cash flow
- In fiscal 2025 operations used $25.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Sera Prognostics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Sera Prognostics, Inc. does
Sera Prognostics, Inc. is registered with the SEC under industry code SIC 8071 (Services-Medical Laboratories). Its shares trade on NASDAQ under the ticker SERA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $81K | -$31.9M | -$0.67 | -$26.3M |
| 2024 | $77K | -$32.9M | -$0.99 | -$14.2M |
| 2023 | $306K | -$36.2M | -$1.16 | -$27.3M |
| 2022 | $268K | -$44.2M | -$1.43 | -$35.4M |
| 2021 | $82K | -$35M | -$2.33 | -$32.9M |
| 2021 | $25K | -$19.8M | -$12.76 | -$17M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where SERA ranks in Health care
Latest SEC filings
What Sera Prognostics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 19, 2026
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 76% to $30K versus the same quarter last year; diluted EPS -$0.18 versus -$0.16.
- August 12, 2026
- July 15, 2026Passive stake changed SCHEDULE 13G/A
- June 30, 2026
- June 4, 2026
- June 1, 2026Additional proxy material DEFA14A
- June 1, 2026
- May 6, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 63% to $14K versus the same quarter last year; diluted EPS -$0.17 versus -$0.20.
- May 6, 2026
Insider trades
What the people running Sera Prognostics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $63.3K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 10, 2026 | Jackson BenjaminGeneral Counsel | Sold | 2,190 | $4.4K |
| September 10, 2026 | Lindgardt ZhenyaChief Executive Officer, Director | Sold | 7,022 | $14K |
| September 10, 2026 | Anderson Dyaarl Lee Jr.Chief Commercial Officer | Sold | 1,800 | $3.6K |
| September 10, 2026 | Inglis Tiffany Eul DavisChief Medical Officer | Sold | 486 | $972 |
| September 8, 2026 | Lindgardt ZhenyaChief Executive Officer, Director | Sold | 20,139 | $40.3K |
| August 31, 2026 | Gleason ScottChief Financial Officer | Received as pay | 117,924 | - |
| July 10, 2026 | Critchfield Gregory CDirector | Received as pay | 22,426 | - |
| July 10, 2026 | Critchfield Gregory CDirector | Received as pay | 1,594 | - |
Who owns SERA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Baker Bros. Advisors LP13D, may seek influence with 3 related filers | 16.1% | February 14, 2025 |
| Whetstone Capital Advisors, LLC13G, passive with 1 related filers | 8.6% | May 1, 2026 |
| Chione Ltd.13D, may seek influence with 4 related filers | 7.6% | February 14, 2025 |
| Aberdeen Group plc13G, passive with 1 related filers | 7.21% | July 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 46 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Baker Bros. Advisors LP | 5,498,170 | 0 |
| Whetstone Capital Advisors, LLC | 3,306,889 | 0 |
| Aberdeen Group plc | 2,753,525 | +202,750 |
| Vivo Capital, LLC | 1,650,440 | 0 |
| Vanguard Capital Management LLC | 1,297,792 | +93,677 |
| Captrust Financial Advisors | 535,755 | -1,006 |
| Geode Capital Management, LLC | 348,967 | -14,650 |
| BlackRock, Inc. | 221,369 | +25,264 |
| AWM Investment Company, Inc. | 207,382 | 0 |
| Vanguard Fiduciary Trust Co | 170,908 | +1,247 |
| State Street Corp | 124,792 | 0 |
| Millennium Management LLC | 73,986 | -17,518 |
| Perigon Wealth Management, LLC | 72,685 | 0 |
| Northern Trust Corp | 68,595 | -27,940 |
| Bank of New York Mellon Corp | 60,927 | 0 |
| Bridgeway Capital Management, LLC | 55,705 | +10,000 |
| Requisite Capital Management, LLC | 55,648 | 0 |
| Morgan Stanley | 50,972 | -54,045 |
| Qube Research & Technologies Ltd | 50,871 | +30,954 |
| Ballentine Partners, LLC | 49,664 | 0 |
Insiders
16 insiders reported holding 3,172,406 shares in total, about $6.9M at the last price.
| Holder | Shares |
|---|---|
| Critchfield Gregory CDirector | 846,886 |
| Lindgardt ZhenyaChief Executive Officer, Director | 837,848 |
| Aerts AustinChief Financial Officer | 301,190 |
| Kearney PaulChief Data Officer | 163,961 |
| Jackson BenjaminGeneral Counsel | 159,566 |
| Boniface John J.Chief Scientific Officer | 145,842 |
| Gleason ScottChief Financial Officer | 117,924 |
| Inglis Tiffany Eul DavisChief Medical Officer | 91,589 |
| Mirza Mansoor RazaDirector | 81,937 |
| Phillips JoshuaDirector | 81,691 |
Questions about SERA
What does Sera Prognostics, Inc. do?
Sera Prognostics, Inc. is a company in the Health care sector, listed on NASDAQ as SERA. Its shares trade on NASDAQ under the ticker SERA.
What is Sera Prognostics, Inc.'s net worth?
Sera Prognostics, Inc. has a market value (market cap) of $86.4M at the latest share price, and shareholders' equity of $59.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Sera Prognostics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $33.2M on revenue of $70K.
How much revenue does Sera Prognostics, Inc. make?
Over the twelve months to June 30, 2026 Sera Prognostics, Inc. reported revenue of $70K. That is 35.2% less than a year earlier.
When did Sera Prognostics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 11, 2026.
When is Sera Prognostics, Inc.'s next earnings report?
Sera Prognostics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare SERA with
Follow SERA
Get an email when Sera Prognostics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Sera Prognostics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.